Bumetanide IM Dosing
For intramuscular administration of bumetanide (Bumex), the initial dose is 1.0 mg, with a maximum single dose of 4 to 8 mg 1, 2, 3.
Dosing Guidelines
The FDA-approved drug label and multiple ACC/AHA heart failure guidelines consistently specify the following IM dosing parameters 4:
- Initial dose: 1.0 mg IM
- Maximum single dose: 4-8 mg
- Frequency: Can be given once to three times daily if needed
- Route equivalence: IM and IV bumetanide produce almost equal diuretic responses 4
Clinical Context for IM Administration
IM bumetanide should be used when gastrointestinal absorption is impaired or oral administration is not practical 4. The parenteral route (IM or IV) is appropriate when:
- Intestinal edema reduces oral bioavailability
- Patient cannot take oral medications
- Rapid diuresis is needed but IV access is problematic
Dose Conversion Considerations
When converting from oral furosemide, bumetanide can be substituted at approximately a 1:40 ratio (1 mg bumetanide = 40 mg furosemide) 4. This is particularly relevant for patients with furosemide allergy, as cross-sensitivity is rare.
Important Safety Considerations
Monitor electrolytes closely, as bumetanide is 40-60 times more potent than furosemide on a milligram basis 4. Key monitoring includes:
- Daily electrolytes (potassium, magnesium, sodium)
- Renal function (creatinine, BUN)
- Volume status and blood pressure
- Ototoxicity risk increases with high doses, especially with renal impairment or concurrent aminoglycosides 4
Transition to oral therapy as soon as the patient can tolerate it 1, as parenteral administration should be temporary.